ChEMBL logo

ChEMBL

spacer
ChEMBL Statistics
  Loading Statistics...
spacer

Compound Report Card

Compound Name and Classification

Compound ID CHEMBL1201202
CHEMBL1201202
Compound Name FONDAPARINUX
ChEMBL Synonyms SR 90107A | FONDAPARINUX SODIUM | FONDAPARINUX | ARIXTRA | ORG 31540
Max Phase 4 (Approved)
Trade Names ARIXTRA | FONDAPARINUX SODIUM
Molecular Formula C31H53N3O49S8

Additional synonyms for CHEMBL1201202 found using NCI Chemical Identifier Resolver

Compound Representations

Molfile Download MolFile
Canonical SMILES CO[C@H]1O[C@H](COS(=O)(=O)O)[C@@H](O[C@@H]2O[C@H]([C@@H](O[C ...
Download SMILES
Standard InChI InChI=1S/C31H53N3O49S8/c1-69-27-9(33-85(48,49)50)13(37)17(6( ...
Download InChI
Standard InChI Key KANJSNBRCNMZMV-ABRZTLGGSA-N

Sources

  • British National Formulary
  • Orange Book
  • Scientific Literature
  • USP Dictionary of USAN and International Drug Names
  • WHO Anatomical Therapeutic Chemical Classification

Alternate Forms of Compound in ChEMBL


CHEMBL1201202

Molecule Features

CHEMBL1201202 compound icon
Drug Type:Oligosaccharide Rule of Five:N First In Class:N Chirality:Single Stereoisomer Prodrug:N Oral:N Parenteral:Y Topical:N Black Box:Y Availability Type:Prescription-only

Mechanism of Action

Mechanism of Action ChEMBL Target References
Antithrombin-III activator Antithrombin-III FDA

Indications

MESH Heading MESH ID EFO ID EFO Term Max phase for indication References
Renal InsufficiencyD0514371ClinicalTrials
ClinicalTrials
Venous ThromboembolismD054556EFO:0004286venous thromboembolism3ClinicalTrials
ClinicalTrials
Ovarian NeoplasmsD010051EFO:0001075ovarian carcinoma1ClinicalTrials
Obesity, MorbidD009767EFO:0001074morbid obesity1ClinicalTrials
ThrombocytopeniaD0139212ClinicalTrials
ThrombosisD013927HP:0004419Recurrent thrombophlebitis4ATC
Venous ThrombosisD020246HP:0004936Venous thrombosis3ClinicalTrials
ClinicalTrials
Atrial FibrillationD001281EFO:0000275atrial fibrillation2ClinicalTrials
Venous ThrombosisD020246EFO:0003907deep vein thrombosis3ClinicalTrials
Acute Coronary SyndromeD054058EFO:0005672acute coronary syndrome3ClinicalTrials
Pulmonary EmbolismD011655EFO:0003827pulmonary embolism3ClinicalTrials

Clinical Data

ClinicalTrials.gov FONDAPARINUX
The Cochrane Collaboration FONDAPARINUX

Compound Bioactivity Summary

Compound Assay Summary

Compound Target Summary

Calculated Compound Parent Properties

Mol. Weight Mol. Weight Monoisotopic ALogP #Rotatable Bonds Polar Surface Area Molecular Species
1508.3 1506.9513 - - - -


HBA HBD #Ro5 Violations HBA (Lipinski) HBD (Lipinski) #Ro5 Violations (Lipinski)
- - - - - -


ACD Acidic pKa ACD Basic pKa ACD LogP ACD LogD pH7.4 Aromatic Rings Heavy Atoms QED Weighted
- - - - - - -0

Structural Alerts

There are no structural alerts for CHEMBL1201202

Compound Cross References

ATC B - BLOOD AND BLOOD FORMING ORGANS
B01 - ANTITHROMBOTIC AGENTS
B01A - ANTITHROMBOTIC AGENTS
B01AX - Other antithrombotic agents
B01AX05 - fondaparinux

ChemSpider ChemSpider:KANJSNBRCNMZMV-ABRZTLGGSA-N
DailyMed fondaparinux sodium
Wikipedia Fondaparinux

UniChem Cross References

View the UniChem Connectivity matches for CHEMBL1201202



Brenda 117819 167802
ChEBI 61033
DrugBank DB00569
DrugCentral 1236
EPA CompTox Dashboard DTXSID10146903
FDA SRS J177FOW5JL
Guide to Pharmacology 6819
Human Metabolome Database HMDB0014709
IBM Patent System D170E730A51AE499E171F5FEF8ABF447
Nikkaji J862.320A
PDBe NTO
PubChem 5282448
PubChem: Thomson Pharma 14792964
SureChEMBL SCHEMBL17655218

UniChem REST Service Call:
https://www.ebi.ac.uk/unichem/rest/verbose_inchikey/KANJSNBRCNMZMV-ABRZTLGGSA-N spacer
spacer